Chemosensitization by antisense oligonucleotides targeting MDM2

Current Cancer Drug Targets

Volumn 5, Issue 1, 2005, Pages 51-56

  Bianco, Roberto ^a   Ciardiello, Fortunate ^b   Tortora, Giampaolo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CHEMOSENSITIZING AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GENE PRODUCT; POLYPEPTIDE; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN MDM2 ANTISENSE OLIGONUCLEOTIDE; PROTEIN MDM2 INHIBITOR; PROTEIN P53; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER RADIOTHERAPY; CANCER THERAPY; CELL PROLIFERATION; CHEMOSENSITIZATION; COLON CANCER; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIZATION; DRUG TARGETING; GENE ACTIVATION; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HEMATOLOGIC MALIGNANCY; HORMONE RESISTANCE; HORMONE SENSITIVITY; HUMAN; NONHUMAN; ONCOGENE; ONCOGENE MDM2; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; RADIOSENSITIZATION; REVIEW; SARCOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; GENE THERAPY; HUMANS; NEOPLASMS; NUCLEAR PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2;

EID: 14644439903     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009053332681     Document Type: Review

References (49)

1. Donehower, L. A.; Bradley, A. The tumor suppressor p53. Biochim. Biophys. Acta 1993, 1155, 181-205.
2. Vogelstein, B.; Kinzler, K. W. p53 function and dysfunction. Cell 1992, 70, 523-526.
3. Lane, D. P. Cancer. p53, guardian of the genome. Nature 1992, 358, 15-16.
4. Livingstone, L. R.; White, A.; Sprouse, J.; Livanos, E.; Jacks, T.; Tlsty, T. D. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992, 70, 923-935.
5. Kastan, M. B.; Zhan, Q.; el-Deiry, W. S.; Carrier, F.; Jacks, T.; Walsh, W. V.; Plunkett, B. S.; Vogelstein, B.; Fornace, A. J. Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992, 71, 587-597.
6. Wu, X.; Bayle, J. H.; Olson, D.; Levine, A. J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 1993, 7, 1126-1132.
7. Fornace, A. J. Jr.; Nebert, D. W.; Hollander, M. C.; Luethy, J. D.; Papathanasiou, M.; Fargnoli, J.; Holbrook, N. J. Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents. Mol. Cell Biol. 1989, 9, 4196-4203.
8. El-Deiry, W. S.; Harper, J. W.; O'Connor, P. M.; Velculescu, V. E.; Canman, C. E.; Jackman, J.; Pietenpol, J. A.; Burrell, M.; Hill, D. E.; Wang, Y. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994, 54, 1169-1174.
9. Hollstein, M. D.; Sidransky, D.; Vogelstein, B.; Harris, C.C. p53 mutations in human cancers. Science, 1991, 253, 49-53.
10. Akslen, L. A.; Morkve, O. Expression of p53 protein in cutaneous melanoma. Int. J. Cancer 1992, 52, 13-16.
11. Kovach, J. S.; Hartmann, A.; Blaszyk, H.; Cunningham, J.; Schaid, D.; Sommer, S. S.; Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc. Natl. Acad. Sci. USA 1996, 93, 1093-1096.
12. Kastan, M. B.; Onyekwere, O.; Sidransky, D.; Vogelstein, B.; Craig, R. W.; Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991, 51, 6304-6311.
13. Clarke A. R.; Purdie, C. A.; Harrison, D. J.; Morris, R. G.; Bird, C. C.; Hooper, M. L.; Wyllie, A. H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993, 362, 849-852.
14. Di Leonardo, A.; Linke, S. P.; Clarkin, K.; Wahl, G. M. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev. 1994, 5, 2540-2551.
15. Kuerbits, S. J.; Plunkett, B. S.; Walsh, W. V.; Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 1992, 89, 7491-7495.
16. O'Connor, P. M.; Jackman, J.; Bae, I.; Myers, T. G.; Fan, S.; Mutoh, M.; Scudiero, D. A.; Monks, A.; Sausville, E. A.; Weinstein, J. N.; Friend, S.; Fornace, A. J.; Khon, K. W. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 1997, 57, 4285-4300.
17. Hupp, T. R.; Lane, D. P.; Ball, K. L. Strategies for manipulating the p53 pathway in the treatment of human cancer. Biochem. J. 2000, 352, 1-17.
18. Lane, D.; Lain, S. Therapeutic exploitation of the p53 pathway. Trends Molec. Med. 2002, 8, S38-S42.
19. Lang, F. F.; Yung, W. K.; Raju, U.; Libunao, F.; Terry, N. H.; Tofilon, P. J. Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene. J. Neurosurg. 1998, 89, 125-132.
20. Muschel, R. J.; Soto, D. E.; McKenna, W. G.; Bernhard, E. J. Radiosensitization and apoptosis. Oncogene 1998, 17, 3359-3363.
21. Zhang, R.; Wang, H. MDM2 oncogene as a novel target for human cancer therapy. Curr. Pharm. Design 2000, 6, 393-416.
22. Chène, P. Inhibiting the p53-MDM2 interaction: An important target for cancer therapy. Nat. Rev. Cancer 2003, 3, 102-109.
23. Vassilev, L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E. A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 30, 844-848.
24. Chen, L.; Agrawal, S.; Zhou, W.; Zhang, R.; Chen, J. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc. Natl. Acad. Sci. USA 1998, 95, 195-200.
25. Wang, H.; Zeng, X.; Oliver, P.; Le, L. P.; Chen, J.; Chen, L.; Zhou, W.; Agrawal, S.; Zhang, R. MDM2 oncogene as a target for cancer therapy: an antisense approach. Intl. J. Onc. 1999, 15, 653-660.
26. Tortora, G.; Caputo, R.; Damiano, V.; Bianco, R.; Chen, J.; Agrawal, S.; Bianco, A. R.; Ciardiello, F. A novel mdm2 antisense oligonucleotide has antitumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer. Intl. J. Cancer 2000, 88, 804-809.
27. Wang, H.; Nan, L.; Yu, D.; Agrawal, S.; Zhang, R. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. Clin. Cancer Res. 2001, 7, 3613-3624.
28. Osman, I.; Drobnjak, M.; Fazzari, M.; Ferra, J.; Scher, H. I.; Cordon-Cardo, C. Inactivationof the p53 pathway in prostate cancer: Impact on tumor progression. Clin. Cancer Res. 1999, 5, 2082-2088.
29. Zhang, Z.; Li, M.; Wang, H.; Agrawal, S.; Zhang, R. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression and chemotherapy. Proc. Natl. Acad. Sci. USA 2003, 100, 11636-11641.
30. Wang, H.; Yu, D.; Agrawal, S.; Zhang, R. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms. The Prostate 2003, 5, 194-205.
31. Mu, Z.; Hachmen, P.; Agrawal, S.; Pollack, A. Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation. The Prostate 2004, 60, 187-196.
32. Mendelsohn, J.; Baselga, J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 2003, 21, 2787-2799.
33. Sher, H. I.; Sarkis, A.; Reuter, V.; Cohen, D.; Netto, G.; Petrylak, D.; Lianes, P.; Fuks, Z.; Mendelsohn, J.; Cordon-Cardo, C. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor α in the progression of prostatic neoplasms. Clin. Cancer Res. 1995, 1, 545-550.
34. Barton, J.; Blackledge, G.; Wakeling, A. Growth factors and their receptors: New targets for prostate cancer therapy. Urology 2001, 58, 114-122.
35. Di Lorenzo, G.; Tortora, G.; D'Armiento, F. P.; De Rosa, G.; Staibano, S.; Autorino, R.; D'Armiento, M.; De Laurentiis, M.; De Placido, S.; Catalane, G.; Bianco, A. R.; Ciardiello, F. Expression of epidermal growth factor receptor (EGFR) correlates with disease relapse and progression to androgen-indepedence in human prostate cancer. Clin. Cancer Res. 2002, 8, 3438-3444.
36. Sirotnak, F. M.; She, Y.; Lee, F.; Chen, J.; Scher, H. I. Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer. Clin. Cancer Res. 2002, 8, 3870-3876.
37. Ciardiello, F. and Tortora, G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. 2001, 7, 2958-2970.
38. Ciardiello, F.; Caputo, R.; Bianco, R.; Damiano, V.; Fontanini, G.; Cuccato, S.; De Placido, S.; Bianco, A. R.; Tortora, G. Inhibition of growth factors production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res. 2001, 7, 1459-1465.
39. Palmero, I.; Pontoja, C.; Serrano, M. p19ARF links the tumor suppressor p53 to ras. Nature 1998, 39, 125-126.
40. Ries, S.; Biederer, C.; Woods, D.; Shifman, O.; Shirasawa, S.; Sasazuki, T.; McMahon, M.; Oren, M.; McCormick, F. Opposing effects of ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 2000, 103, 321-330.
41. Bianco, R.; Caputo, R.; Caputo, R.; Damiano, V.; De Placido, S.; Ficorella, C.; Agrawal, S.; Bianco, A. R.; Ciardiello, F.; Tortora, G. Combined targeting of Epidermanl Growth Factor Receptor and MDM2 by Gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer. Clin. Cancer Res. 2004, 10, 4858-4864.
42. Xiao, Z.; Chen, J.; Levine, A. J.; Modjtahedi, N.; Xing, J.; Seliers, W. R.; Livingston, D. M. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995,375, 694-698.
43. McCann, A. H.; Kirley, A.; Carney, D. N.; Corbally, N.; Magee, H. M.; Keating, G.; Darvan, P. A. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br. J. Cancer 1995, 71, 981-985.
44. Peng, Y.; Chen, L.; Li, C.; Lu, W.; Agrawal, S.; Chen, J. Stabilization of the MDM2 oncoprotein by mutant p53. J. Biol. Chem. 2001, 276, 6874-6878.
45. McKenzie, P.; McPake, C.; Ashford, A. A.; Vanin, E. F.; Harris, L. C. MDM2 does not influence p53-mediated sensitivity to DNA-damaging drugs. Mol. Cancer Ther. 2002, 1, 1097-1104.
46. Freedman, D.; A; Levine, A. J. Regulation of the p53 protein by the MDM2 oncoprotein. Thirty-eight G.H.A. Clowes Memorial Award Lecture. Clin. Cancer Res. 1999, 5, 1-7.
47. Martin, I. C.; Trouche, D.; Hagemeier, C.; Sorensen, T. S.; La Thangue, N. B.; Kouzarides, T. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 1995, 37, 691-694.
48. Zhang, Z.; Wang, H.; Li, M.; Agrawal, S.; Chen, X.; Zhang, R. MDM2 as a negative regulator of p21WAF1/CIP1, independent of p53. J. Biol. Chem. 2004, 279, 16000-16006.
49. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998, 92, 713-723.